CHU Hautepierre

Strasbourg 67200

0 studies enrolling now · 6 studies all time

What they study most

Assess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients., B-Cell Chronic Lymphocytic Leukemia, Congenital Bleeding Disorder, Diffuse Cutaneous Systemic Sclerosis, Haemophilia B, Lupus Erythematosus, Systemic, Primary Sclerosing Cholangitis

Studies at this site

• Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) — Completed
• Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B — Completed
• A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus — Completed
• Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) — Withdrawn before enrolling
• Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) — Completed
• Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication — Completed